MCID: CRB039
MIFTS: 67

Cerebrovascular Disease

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An artery disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to peripheral artery disease and vascular dementia, and has symptoms including headache, transient ischemic attacks, stereotypic symptoms and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA
Long non-coding RNA HOTAIR promotes ischemic infarct induced by hypoxia through up-regulating the expression of NOX2.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Zinc and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 76 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 33.0 ACE APOB CRP SELP
2 vascular dementia 32.8 ACE APOE APP MTHFR NOTCH3 PON1
3 cerebral atherosclerosis 31.9 ACE APOA1 APOE MTHFR
4 sleep apnea 31.4 ACE APOE CRP
5 endocarditis 30.9 CRP F2 PLAT
6 portal vein thrombosis 30.9 F2 MTHFR SELP
7 thrombosis 30.9 F2 MTHFR PLAT SELP
8 migraine with aura 30.8 ACE F2 MTHFR NOTCH3
9 hemorrhage, intracerebral 30.8 ACE APOE APP COL4A1 PLAT
10 ischemia 30.7 ACE APP PLAT PON1 SELP
11 sudden sensorineural hearing loss 30.7 F2 MTHFR
12 homocysteinemia 30.6 CBS CRP F2 MTHFR MTR
13 thrombophilia due to thrombin defect 30.6 CBS F2 MTHFR PLAT
14 carotid stenosis 30.6 ACE APOE CRP MTHFR SELP
15 ischemic heart disease 30.6 ACE APOA1 APOB APOE CRP F2
16 carotid artery disease 30.5 ACE APOA1 APOB APOE CRP
17 dementia, lewy body 30.5 APOE APP CBS
18 thrombophilia 30.5 CBS F2 MTHFR PLAT
19 atrial fibrillation 30.4 ACE AGTR1 F2 PLAT SELP
20 coronary heart disease 1 30.2 ACE APOA1 APOB APOE CRP CX3CR1
21 acute myocardial infarction 30.0 ACE AGTR1 APOA1 CRP PLAT SELP
22 stroke, ischemic 29.9 ACE AGTR1 APOB APOE CRP F2
23 diabetes mellitus, noninsulin-dependent 29.5 ACE AGTR1 APOA1 APOB APOE CRP
24 arteries, anomalies of 29.4 ACE AGTR1 APOA1 APOB APOE CRP
25 coronary artery anomaly 29.1 ACE AGTR1 APOA1 APOB APOE CBS
26 congestive heart failure 28.9 ACE ADM AGTR1 HOTAIR
27 diabetes mellitus 28.9 ACE AGTR1 APOA1 APOB CRP MEG3
28 vascular disease 28.6 ACE APOA1 APOB APOE CBS CRP
29 heart disease 27.8 ACE ADM AGTR1 APOA1 APOB APOE
30 myocardial infarction 27.8 ACE ADM AGTR1 APOA1 APOB APOE
31 basal ganglia cerebrovascular disease 12.0
32 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.6
33 moderate and severe traumatic brain injury 11.2 ACE APOE
34 malignant otitis externa 11.2 CRP F2
35 senile plaque formation 11.2 APOE APP
36 porencephaly 11.1 COL4A1 F2 MTHFR
37 ischemic neuropathy 11.1 CRP F2 MTHFR
38 hepatoportal sclerosis 11.1 ACE F2
39 fabry disease 11.1
40 binswanger's disease 11.1 APOE APP NOTCH3
41 retinal vascular occlusion 11.1 F2 MTHFR SELP
42 spinal cord infarction 11.1 F2 MTHFR
43 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 11.1 MTHFR MTR
44 marantic endocarditis 11.1 F2 MTHFR PLAT
45 intracranial vasospasm 11.1 APOE PLAT
46 thrombophlebitis 11.1 F2 MTHFR PLAT
47 nutritional deficiency disease 11.1 CRP F2 MTHFR
48 thrombasthenia 11.1 F2 MTHFR SELP
49 xanthoma disseminatum 11.1 APOB APOE
50 gait apraxia 11.1 APOE APP CBS

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


headache, transient ischemic attacks, stereotypic symptoms, angina pectoris, back pain, chest pain, edema, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 APOE AGTR1 ACE APOA1 APOB ADM
2 homeostasis/metabolism MP:0005376 10.41 APOE AGTR1 ACE APOA1 APOB ADM
3 behavior/neurological MP:0005386 10.29 ADM APOE AGTR1 ACE COL4A1 F2
4 growth/size/body region MP:0005378 10.29 APOE AGTR1 ACE APOB COL4A1 F2
5 immune system MP:0005387 10.27 APOE AGTR1 ACE APOB ADM COL4A1
6 cellular MP:0005384 10.26 APOB ADM APOA1 APP CX3CR1 COL4A1
7 mortality/aging MP:0010768 10.25 ADM APOE AGTR1 ACE APOB COL4A1
8 hematopoietic system MP:0005397 10.24 ADM APOE AGTR1 ACE COL4A1 F2
9 integument MP:0010771 10.13 APOE APOA1 ADM F2 APP CX3CR1
10 nervous system MP:0003631 10.06 APOE AGTR1 APOB CX3CR1 COL4A1 F2
11 muscle MP:0005369 9.97 ADM APOE APOB COL4A1 APP CX3CR1
12 reproductive system MP:0005389 9.9 APOE ACE APOB ADM COL4A1 F2
13 renal/urinary system MP:0005367 9.86 ADM APOE AGTR1 ACE COL4A1 CX3CR1
14 respiratory system MP:0005388 9.5 ADM COL4A1 APOE NOTCH3 SELP F2
15 vision/eye MP:0005391 9.23 APOB CX3CR1 COL4A1 APOE NOTCH3 SELP

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 867)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
2
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
3
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55142-85-3 5472
4
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
5
alemtuzumab Approved, Investigational Phase 4 216503-57-0
6
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
7
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
8
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
9
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
10
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
11
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
12
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
13
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
14
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 81-81-2 6691 54678486
15
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6 772 46507594
16
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
17
Valsartan Approved, Investigational Phase 4,Phase 2,Not Applicable 137862-53-4 60846
18
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
19
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
20
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-93-5 3639
21
Nimodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 66085-59-4 4497
22
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
23
Galantamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 357-70-0 9651
24
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-41-2 439260
25
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
26
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
27
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
28 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7491-74-9
29
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Not Applicable 59467-70-8 4192
30
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
32
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 113775-47-6 68602 5311068
33
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
34
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 124-94-7 31307
35
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 55-63-0 4510
36
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
37
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 103-90-2 1983
38
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
39
Everolimus Approved Phase 4,Phase 2,Phase 3,Not Applicable 159351-69-6 6442177
40
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
41
Apixaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 503612-47-3 10182969
42
Histamine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 75614-87-8, 51-45-6 774
43
Bupropion Approved Phase 4,Not Applicable 34841-39-9, 34911-55-2 444
44
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
45 Nadroparin Approved, Investigational Phase 4,Phase 3 9041-08-1
46
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
47
Probucol Approved, Investigational Phase 4 23288-49-5 4912
48
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
49
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
50
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158

Interventional clinical trials:

(show top 50) (show all 4560)
# Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
3 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
4 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
5 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
6 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
7 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
8 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
9 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
10 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
11 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
12 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
13 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
14 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
15 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
16 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
17 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
18 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
19 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
20 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
21 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
22 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
23 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
24 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
25 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
26 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
27 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
28 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
29 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
30 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
31 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
32 Clopidogrel for Acute Ischaemia of Recent Onset Unknown status NCT02776540 Phase 4 Clopidogrel;Aspirin
33 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
34 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
35 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
36 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
37 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
38 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
39 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
40 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
41 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
42 Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
43 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
44 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
45 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
46 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
47 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
48 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
49 The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels Unknown status NCT01926834 Phase 4 Erigeron Injection;placebo
50 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

41
Brain, Heart, Testes, Bone, Endothelial, Kidney, Bone Marrow

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 866)
# Title Authors Year
1
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
2
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. ( 29600737 )
2018
3
Prevalence, Risk Factors, Outcomes, and Treatment of Obstructive Sleep Apnea in Patients with Cerebrovascular Disease: A Systematic Review. ( 29555400 )
2018
4
Under-utilization of statin medications in patients with peripheral artery disease or cerebrovascular disease. ( 29600738 )
2018
5
Cerebrovascular Disease Knowledge Portal: An Open-Access Data Resource to Accelerate Genomic Discoveries in Stroke. ( 29335331 )
2018
6
Systematic investigation of the Erigeron breviscapus mechanism for treating cerebrovascular disease. ( 29783016 )
2018
7
Association between primary SjAPgren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. ( 29600936 )
2018
8
Revascularization experience and results in ischaemic cerebrovascular disease: Moyamoya disease and carotid occlusion. ( 29550248 )
2018
9
Improvement of postoperative cognitive dysfunction and attention network function of patients with ischemic cerebrovascular disease via dexmedetomidine. ( 29599834 )
2018
10
Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. ( 29310864 )
2018
11
The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults. ( 29861211 )
2018
12
Controversies in cerebrovascular disease: High or low doses of recombinant tissue plasminogen activator to treat acute stroke? A literature review. ( 29891335 )
2018
13
Association Between Heart Rate and Subclinical Cerebrovascular Disease in the Elderly. ( 29284731 )
2018
14
High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. ( 29769642 )
2018
15
Survival after in-hospital cardiac arrest among cerebrovascular disease patients. ( 29789199 )
2018
16
Migraine and cerebrovascular disease: still a dangerous connection? ( 29904830 )
2018
17
More Than Meets the Eye: Cerebrovascular Disease in Sickle Cell Disease Is About More Than Sickling. ( 29695469 )
2018
18
Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable. ( 29696578 )
2018
19
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( 29311290 )
2018
20
Preeclampsia Increases the Incidence of Postpartum Cerebrovascular Disease in Korean Population. ( 29349936 )
2018
21
Cognitive deterioration in schizophrenia: aging and cerebrovascular disease. ( 29936917 )
2018
22
Lower body functioning and correlates among older American Indians: The Cerebrovascular Disease and Its Consequences in American Indians Study. ( 29304750 )
2018
23
Outcomes After Percutaneous Coronary Intervention in Patients With a History of Cerebrovascular Disease: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. ( 29895601 )
2018
24
The effect of demographic features on aortic arch anatomy and its role in the etiology of cerebrovascular disease. ( 29302189 )
2018
25
On the Reproducibility of Inversion Recovery Intravoxel Incoherent Motion Imaging in Cerebrovascular Disease. ( 29217741 )
2018
26
Comparison of Blood Oxygenation Level-Dependent fMRI and Provocative DSC Perfusion MR Imaging for Monitoring Cerebrovascular Reserve in Intracranial Chronic Cerebrovascular Disease. ( 29371256 )
2018
27
PET imaging of the neurovascular interface in cerebrovascular disease. ( 29611539 )
2018
28
Regional Subclinical Cerebrovascular Disease Is Associated with Balance in an Elderly Multi-Ethnic Population. ( 29953989 )
2018
29
Sir Winston Churchill: cerebrovascular disease January 1950-March 1952. ( 29932355 )
2018
30
Functional Trajectories, Cognition, and Subclinical Cerebrovascular Disease. ( 29374104 )
2018
31
Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. ( 29325730 )
2018
32
The numerical study on specialized treatment strategies of enhanced external counterpulsation for cardiovascular and cerebrovascular disease. ( 29713856 )
2018
33
Moyamoya-like cerebrovascular disease in a child with a novel mutation in myosin heavy chain 11. ( 29263223 )
2018
34
Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. ( 29335630 )
2018
35
Association of Blood Pressure Control Level With Left Ventricular Morphology and Function and With Subclinical Cerebrovascular Disease. ( 28757483 )
2017
36
Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease. ( 28818116 )
2017
37
Effects of aspiration pneumonia on the intensive care requirements and in-hospital mortality of hospitalised patients with acute cerebrovascular disease. ( 28883847 )
2017
38
Letter by Tsuda Regarding Article, "Association of Vegetable Nitrate Intake With Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women". ( 28830972 )
2017
39
Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). ( 28916531 )
2017
40
Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. ( 27980126 )
2017
41
Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study. ( 29213240 )
2017
42
Quantitative susceptibility mapping of the motor cortex: a comparison of susceptibility among patients with amyotrophic lateral sclerosis, cerebrovascular disease, and healthy controls. ( 29018934 )
2017
43
Increased Prevalence of Cerebrovascular Disease in Hospitalized Patients with Ehlers-Danlos Syndrome. ( 28647420 )
2017
44
Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction. ( 28933065 )
2017
45
Positive Airway Pressure Therapy for Hyperventilatory Central SleepA Apnea: Idiopathic, Heart Failure, Cerebrovascular Disease, and High Altitude. ( 29108611 )
2017
46
Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases. ( 29081013 )
2017
47
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( 28072691 )
2017
48
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. ( 28591212 )
2017
49
Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. ( 28074678 )
2017
50
Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease. ( 28816594 )
2017